Shining Light on AAVs: Using Light Scattering Technologies to Solve Challenges in Characterization
With the rising clinical and commercial successes of AAV-based gene therapies, there is an ever-growing demand for robust, platform analytical technologies that can help ensure better product quality, safety, and efficacy. Size exclusion chromatography (SEC) and Field Flow Fractionation (FFF), coupled with multi-angle light scattering technologies (MALS), are rapidly emerging as transformative technologies for rapid and accurate characterization of AAV samples. Critical Quality Attributes (CQAs) such as capsid titer, genome titer, empty/full, % aggregation and purity of various AAV serotypes can all be obtained in a single measurement. This multi-attribute approach dramatically reduces operational costs and reduces drug development timelines.
Key Learning Objectives:
- See how SEC-MALS compares to orthogonal techniques (ddPCR, Capsid ELISA’s, and AUC) for the characterization of AAV during various downstream steps
- Understand how light scattering can be used as a rapid screening tool when working with multiple AAV serotypes
- Appreciate the value of FFF-MALS for accurate, AAV aggregation analysis
Who Should Attend:
- Academic researchers involved in biophysical studies
- Academic researchers involved in gene therapy studies
- Gene Therapy - Discovery
- Gene Therapy - Development
- Gene Therapy – QC
- Government researchers involved in gene therapy research
Brought to you by:
Speakers:
Sr. Staff Scientist,
Research & Development Dept. of Patheon (by Thermo Fisher Scientific) Viral Vector Services
Lead Scientist,
Research & Development Dept. of Patheon (by Thermo Fisher Scientific) Viral Vector Services
Forensic Science Consultant,
C&EN Media Group
Event has ended
You can no longer attend this event.
Start:
Wed, Oct 18, 2023 11:00 AM EDT
End:
Wed, Oct 18, 2023 12:00 PM EDT
<a href='https://connect.discoveracs.org/CENWebinar_WyattTechnology_10_18_23?partnerref=WebinarsHub'>Register</a>
